NCT06367738

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Name: Clinical Trial NCT06367738
Creator: University of California, Berkeley
Keywords: Aging, Psilocybin, Phase 1, drug, clinical trial

University of California, Berkeley·Phase 1·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Aging
Drug/Device/Intervention: Psilocybin
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: University of California, Berkeley

Timeline & enrollment

Phase: Phase 1
Start date: Apr 01, 2025
End date: Dec 30, 2027
Enrollment: 40 participants

Primary outcome

MRI measurements of brain structure

Summary

We will use cognitive exams, perceptual tasks, brain imaging, peripheral psychophysiology, and surveys to investigate the persisting effects of psilocybin on cognition, predictive coding, and affect in healthy older adults. We will measure changes in these measures by comparing baseline to one-week and one-month post-treatment. Participants will be randomly assigned to receive a dose of psilocybin in a range from microdose to moderate-to-high dose. Dose response will be assessed. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity. We will assess whether changes in these brain measures underlie observed changes in cognition, predictive coding and affect.

ICD-10 classifications

Alzheimer diseaseAgenesis and underdevelopment of noseAgenesis of lungAdult-onset Still diseaseChoroidal degeneration

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06367738
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06367738 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of California, Berkeley and is currently Not yet recruiting. The study focuses on Aging. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.